QuickCool AB is a medtech company based at Ideon Science Park in Lund, Sweden.
The company has developed a patented brain and body cooling system primarily for sudden cardiac arrest patients. Other potential future indications are stroke and sepsis.
QuickCool’s cooling system is based on a proprietary method. Balloon catheters inserted into the nasal cavity are used to circulate cold saline solution, utilizing the nasal cavity's heat exchanging properties to manage the body temperature.
QuickCool is a young medtech company active in the field of therapeutic cooling, a process that aims to protect the brain. The company was founded in 2003 by the professors Anders Lunderquist and Tadeusz Wieloch; senior physician Fredrik Boris-Möller; economist Lennart Sjölund and perfusionist Mats Allers.
Research is the basis for QuickCool. The founders’ complementary expertise contributed to the development of innovative medical technology for the rapid therapy of patients in need of therapeutic cooling.
The research began in the late 1980s when Tadeusz Wieloch and Fredrik-Boris Möller were at Lund University, and showed how cooling alleviates brain damage in experimental models for cardiac arrest and stroke. Cooling the brain can prevent many harmful mechanisms triggered by oxygen deprivation arising from critical illnesses such as cardiac arrest and brain injury.
Around 2000, the company’s founders began to think about ways to combine the team’s knowledge on brain protective therapy with experience of developing heart-lung equipment for cooling blood and fluids. From 2003 to 2006, a number of pre-clinical tests were conducted to increase understanding of the central principles relating to therapy involving cooling and to show proof-of-principle in animal models for a newly developed method to cool via the nasal cavity. Most of these pre-clinical studies have been published in international research journals. QuickCool’s activities are thus based on solid scientific foundations.
The new knowledge obtained from the pre-clinical tests was the basis for a series of clinical trials both in Sweden and abroad with the aim to optimize the nasal cavity cooling system for human applications. The first clinical trial on cardiac arrest patients took place at Uppsala University Hospital in 2007. From 2007 to 2011, a number of clinical studies were conducted on further developed equipment and the cooling method – everything from advanced volunteer studies using MRI scanning to smaller clinical trials on cardiac arrest and trauma patients in need of cooling. QuickCool sponsored the EU project ARISE (2007–2013) and EUROHYP-1. During this period, there was continuous development of the balloon catheter design, and in 2010 a new CE-marked cooling device, ComVic, was introduced. This product was primarily intended to be used for clinical trials and to get user input. QuickCool’s cooling system has been designed with input from users, to be easy to use and gentle on the patient. It does not cover the patient’s body with cooling bags. It offers a portable system that delivers continuous temperature management.
In 2013, the Target Temperature Management (TTM) study was published in the respected research journal The New England Journal of Medicine. The results from this multi-center study received wide attention, as they showed that cooling for cardiac arrest patients was equally effective at approx. 36°C as it was at 33°C. Cooling to 36°C is closer to normal body temperature and could possibly avoid risks associated with lower temperatures. This in turn opens the way for using TTM in new clinical applications, such as stroke.
QuickCool applied this finding in the development of a compact, portable temperature management system. In December 2015, QuickCool was listed on AktieTorget (now Spotlight Stock Market) and since then the company has been financed to facilitate the development and launch of a commercial temperature management system. The company’s new generation cooling offers an easy-to-use portable system for gentle and controlled temperature management at 36°C.